GenMark Diagnostics, Inc (NASDAQ:GNMK) Shares Bought by California Public Employees Retirement System

California Public Employees Retirement System grew its holdings in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 18.1% in the third quarter, Holdings Channel reports. The institutional investor owned 71,262 shares of the medical equipment provider’s stock after purchasing an additional 10,944 shares during the period. California Public Employees Retirement System’s holdings in GenMark Diagnostics were worth $432,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Man Group plc increased its holdings in shares of GenMark Diagnostics by 1.7% in the 2nd quarter. Man Group plc now owns 146,100 shares of the medical equipment provider’s stock valued at $948,000 after acquiring an additional 2,400 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of GenMark Diagnostics by 5.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 58,888 shares of the medical equipment provider’s stock worth $357,000 after acquiring an additional 3,287 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of GenMark Diagnostics by 20.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 21,700 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 3,700 shares in the last quarter. Bank of Montreal Can lifted its stake in GenMark Diagnostics by 145.4% during the second quarter. Bank of Montreal Can now owns 7,687 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 4,554 shares during the last quarter. Finally, Stephens Inc. AR lifted its stake in GenMark Diagnostics by 24.3% during the second quarter. Stephens Inc. AR now owns 36,795 shares of the medical equipment provider’s stock worth $239,000 after purchasing an additional 7,193 shares during the last quarter. 90.92% of the stock is owned by institutional investors.

A number of research firms have weighed in on GNMK. Zacks Investment Research cut shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. ValuEngine upgraded shares of GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 19th. Finally, BidaskClub downgraded shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, November 2nd. Three research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $9.67.

In other GenMark Diagnostics news, COO Scott Mendel sold 5,206 shares of GenMark Diagnostics stock in a transaction on Monday, November 25th. The shares were sold at an average price of $5.43, for a total value of $28,268.58. Following the transaction, the chief operating officer now directly owns 330,663 shares in the company, valued at $1,795,500.09. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Sarah Hollis Winkler sold 5,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $5.62, for a total transaction of $30,910.00. Following the completion of the sale, the vice president now directly owns 56,292 shares of the company’s stock, valued at $316,361.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,268 shares of company stock valued at $272,529. 5.24% of the stock is owned by company insiders.

GNMK opened at $5.55 on Friday. GenMark Diagnostics, Inc has a one year low of $3.58 and a one year high of $8.37. The company has a debt-to-equity ratio of 6.40, a quick ratio of 2.11 and a current ratio of 2.69. The stock has a market capitalization of $320.02 million, a P/E ratio of -6.10 and a beta of 1.17. The business’s 50-day simple moving average is $5.64 and its 200-day simple moving average is $6.14.

GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $20.92 million during the quarter, compared to analyst estimates of $20.66 million. GenMark Diagnostics had a negative net margin of 60.63% and a negative return on equity of 239.16%. On average, equities research analysts forecast that GenMark Diagnostics, Inc will post -0.81 EPS for the current fiscal year.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Read More: Why does a company issue an IPO?

Want to see what other hedge funds are holding GNMK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GenMark Diagnostics, Inc (NASDAQ:GNMK).

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit